MRZ-9547

MRZ-9547
Clinical data
Other names	(R)-Phenylpiracetam; (R)-Phenotropil; (R)-Fenotropil; (R)-Fonturacetam; Arfonturacetam; N-Carbamoylmethyl-4(R)-phenyl-2-pyrrolidinone
Drug class	Atypical dopamine reuptake inhibitor; Pro-motivational agent
Identifiers
	IUPAC name 2-[(4R)-2-oxo-4-phenylpyrrolidin-1-yl]acetamide;
CAS Number	949925-07-9;
PubChem CID	781883;
ChemSpider	683574;
UNII	X4X99EKB3S;
Chemical and physical data
Formula	C12H14N2O2
Molar mass	218.256 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@@H](CN(C1=O)CC(=O)N)C2=CC=CC=C2;
	InChI InChI=1S/C12H14N2O2/c13-11(15)8-14-7-10(6-12(14)16)9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,13,15)/t10-/m0/s1; Key:LYONXVJRBWWGQO-JTQLQIEISA-N;

MRZ-9547, also known as (R)-phenylpiracetam, (R)-phenotropil, or (R)-fonturacetam, is a selective dopamine reuptake inhibitor (IC₅₀Tooltip half-maximal inhibitory concentration = 14.5 μM) that was developed by Merz Pharma. It is the (R)-enantiomer of the racetam and nootropic phenylpiracetam (phenotropil; fonturacetam).

The drug was under development for the treatment of fatigue associated with Parkinson's disease and was in phase 1 clinical trials for this indication in June 2014. However, no recent development has been reported as of November 2017. There was also interest in MRZ-9547 for treatment of fatigue in people with depression and other conditions, but this was not pursued.

Similarly to other dopamine reuptake inhibitors and related agents, MRZ-9547 has been found to have pro-motivational effects in animals and to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine.

The drug, as the enantiopure (R)-enantiomer of phenylpiracetam, was first described in the scientific literature by 2014.